Harper Hubbeling, MD

Jonathan Baron, Gurbani Singh, Francesca Costabile, Carlos Chavez Perez, Miguel Perez-Guillermo Cuev, Emeline Chong, Colin Thomas, Jordan Carter, Sunita Nasta, Daniel Landsburg, Nektarios Kostopoulos, Stefan Barta, Jakub Svoboda, Stephen Schuster, Elise Chong, John Plastaras, Michael LaRiviere, Andrea Facciabene, Harper Hubbeling Low-Dose Hypofractionated Bridging Radiation (4Gy x 2 Fractions) Prior to CAR T-Cell Therapy for Relapsed/Refractory DLBCL , ASTRO 2026 annual meeting: 2026

Jonathan Baron, Monica Chelius, Gurbani Singh, Melanie Berger, Emeline Chong, Colin Thomas, Jordan Carter, Sunita Nasta, Daniel Landsburg, Stefan Barta, Jakub Svoboda, Stephen Schuster, Nikhil Yegya-Raman, Michael LaRiviere, John Plastaras, Elise Chong, Harper Hubbeling Safe Integration of Radiation Therapy with Bispecific Antibodies in Relapsed/Refractory B-cell Lymphomas , ASTRO 2026 Annual Meeting: 2026

Jonathan A Baron, Monica Chelius, MD; Gurbani Singh, MD; Michael D. Schad, MD; Melanie Berger, MD; Emeline R. Chong; Colin J. Thomas, MD; Jordan S. Carter, MD; Michael R. Cook, MD; Sunita D. Nasta, MD; Daniel J. Landsburg, MD; Stefan K. Barta, MD; Jakub Svoboda, MD; Stephen J. Schuster, MD; Nikhil Yegya-Raman, MD; Michael J. LaRiviere, MD; John P. Plastaras, MD, PhD; Elise A. Chong, MD; Harper Hubbeling, MD Safe Integration of Radiation Therapy with Bispecific Antibodies in Relapsed/Refractory B-cell Lymphomas , Clinical Lymphoma, Myeloma and Leukemia: 2026

Jiang C, McWilliams T, Berger M, Lebow ES, Hubbeling H, Azar E, Kolker JD, Nagda SN, Kurtz G, Zou JW, Scheuermann R, Kumar A, Alonso-Basanta M Periventricular radionecrosis after conventionally fractionated radiation for low grade meningiomas , Radiat Oncol: 2026

Patel H, Hubbeling H, Yu K, Carpenter M, LaRiviere MJ, Plastaras JP, Cohen AD, Kapur S, Vogl DT, Waxman AJ, Stadtmauer EA, Garfall AL, Susanibar-Adaniya S Outcomes of radiation integrated with T-cell-engaging bispecific antibodies in relapsed/refractory multiple myeloma , Blood Adv: 2026

Messing I, Linkowski L, Riina MD, Berger M, Baron J, Wang X, Kallan M, Hubbeling HG, Lustig RA, Dorsey JF, Kurtz G, Nagda S, Lukens JN, Flowers A, Lee JYK, Amankulor NM, Jackson C, Mohan S, Amaravadi RK, Schuchter LM, Huang AC, Mitchell TC, Alonso-Basanta M, Lebow ES Outcomes after SRS and ipilimumab plus nivolumab for melanoma brain metastases following prior immune checkpoint inhibitor or targeted therapy , Oncologist: 2026

Jiang C, Hoover T, Baron J, Han X, Li B, Gao Y, Kim M, Hubbeling H, Chong EA, Carter J, Svoboda J, Schuster SJ, Landsburg DJ, Nasta SD, Plastaras J, LaRiviere M Long Term Results of Proton Therapy in Adult Infradiaphragmatic Lymphoma , Int J Part Ther: 2026

Baron JA, Cohen L, Chelius M, Messing I, Mallon J, Tierney A, Elghawy O, Hossain N, Rook A, Villasenor-Park J, Samimi S, Kim E, Hubbeling H, Plastaras JP, Barta SK, LaRiviere M Safety of Concurrent Systemic Therapy and Total Skin Electron Therapy in Cutaneous T-Cell Lymphoma , Clin Lymphoma Myeloma Leuk: 2026

Baron J, Chelius M, Cohen L, Perez CC, Riina M, Ramesh S, Tierney A, Elghawy O, Hossain NM, Rook A, Villasenor-Park J, Samimi S, Kim E, Hubbeling H, Plastaras JP, Barta SK, LaRiviere M Standard Versus Hypofractionated Low-Dose Total Skin Electron Therapy for Cutaneous T-Cell Lymphoma: A Single-Institution Retrospective Analysis , Pract Radiat Oncol: 2026

Friedes C, Berger M, Linkowski L, Hollawell C, Hubbeling H, Alexander D, Kurtz G, Lustig RA, Dorsey JF, Desai AS, Phillips RE, Brem S, Davatzikos C, Nasrallah M, O'Rourke DM, Jackson C, Amankulor NM, Alonso-Basanta M, Mohan S, Bagley SJ, Lebow ES Clinical, molecular, and immunologic determinants of survival in WHO-defined IDH-wildtype glioblastoma treated with radiotherapy: a large real-world cohort study , Neurooncol: 2026